Bright light, better mood? glasses that mimic morning sun tested for depression on dialysis

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient informed about the nature, process, and objectives of the study and having signed a free and informed consent to participate, * Patient treated with conventional hemodialysis for at least 3 months and currently undergoing dialysis 3 times a week, * Patient covered by the french national social welfare Non-Inclusion Criteria: * Patient who has initiated or modified antidepressive treatment within the 4 weeks prior to the inclusion visit, * Patient with initiation of antidepressive treatment within the 10 weeks following the inclusion visit (screening and intervention periods), * Patient who has initiated or modified anxiolytic, hypnotic, or melatonin treatment within the 4 weeks prior to the inclusion visit, * Patient presenting with binocular blindness or age-related macular degeneration (AMD), * Patient receiving medical and/or surgical treatment for a retinal condition, * Patient who has undergone ocular surgery within the 12 weeks prior to the inclusion visit, * Patient scheduled for ocular surgery within the 10 weeks following the inclusion visit (screening and intervention periods), * Patient suffering from neurocognitive disorders, schizophrenia or other primary psychotic disorders, or bipolar disorder or related conditions, * Pregnant or breastfeeding patient, * Patient unable to understand the French language both orally and in writing, making self-assessment impossible, * Patient currently participating in another interventional research protocol, except for the IDE-3D protocol (RIPH2) conducted by the CH Annecy Genevois, * Patient who has already been randomized in the present study, * Patient under guardianship, curatorship, or placed under judicial protection. Randomisation criteria The patient will be considered eligible for randomization if they have a HADS-D screening score dated within a maximum of 15 days and meet one of the following two criteria: * HADS-D screening score ≥ 8 and \< 15, * HADS-D screening score ≥ 15, provided that a medical follow-up assessment has been conducted following this diagnosis during the screening period, and that it does not lead to the recommendation for the initiation or modification of antidepressant treatment and/or psychotherapy within the 10 weeks following the inclusion visit (screening and intervention periods).